GLENMARK:NSE:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1499.85

Change

0.00 (0.00)%

Market Cap

USD 434.87B

Volume

0.85M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-223.90 (-4.08%)

USD 1,533.20B
CIPLA:NSE Cipla Limited

-30.55 (-2.16%)

USD 1,164.75B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-52.95 (-1.61%)

USD 1,092.48B
MANKIND:NSE Mankind Pharma Ltd

-67.75 (-2.76%)

USD 1,000.40B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-22.05 (-1.99%)

USD 953.29B
LUPIN:NSE Lupin Limited

-48.00 (-2.44%)

USD 925.89B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-29.30 (-3.38%)

USD 891.92B
AUROPHARMA:NSE Aurobindo Pharma Limited

-11.30 (-1.02%)

USD 674.02B
ABBOTINDIA:NSE Abbott India Limited

-111.70 (-0.38%)

USD 653.01B
ALKEM:NSE Alkem Laboratories Limited

-128.20 (-2.65%)

USD 583.68B

ETFs Containing GLENMARK:NSE

RAYE Rayliant Quantamental Eme.. 2.08 % 0.00 %

-0.51 (-2.39%)

USD 0.06B
SCIF 0.00 % 0.83 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.10% 77% C+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.10% 77% C+ 77% C+
Trailing 12 Months  
Capital Gain 47.42% 85% B 91% A-
Dividend Return 0.25% 16% F 20% F
Total Return 47.67% 85% B 91% A-
Trailing 5 Years  
Capital Gain 603.99% 82% B 74% C
Dividend Return 5.87% 45% F 27% F
Total Return 609.86% 83% B 73% C
Average Annual (5 Year Horizon)  
Capital Gain 37.68% 68% D+ 56% F
Dividend Return 38.16% 68% D+ 56% F
Total Return 0.48% 47% F 41% F
Risk Return Profile  
Volatility (Standard Deviation) 55.80% 37% F 42% F
Risk Adjusted Return 68.39% 63% D 55% F
Market Capitalization 434.87B 88% B+ 91% A-

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector